{"article": [{"url": "https://www.marketwatch.com/story/regeneron-starts-clinical-study-for-covid-19-antibody-treatment-2020-06-11", "published": 1591860860.0, "headline": "Regeneron starts clinical study for COVID-19 antibody treatment", "body": "Shares of Regeneron Pharmaceuticals Inc. REGN, +0.36% were down 0.1% in premarket trading on Thursday after the company said it started a Phase 1 clinical trial testing its experimental antibody cocktail aimed at both preventing and treating COVID-19. Regeneron plans to test the therapy in hospitalized COVID-19 patients, COVID-19 patients who aren't sick enough to be hospitalized, individuals who are at high risk of contracting the virus, and people who have reported close exposure to someone who has COVID-19. The early-stage trial will have a placebo arm. Regeneron's stock has soared 61.5% year-to-date, while the S&P 500 SPX, +0.87% is down 1.2%."}]}